Cargando…

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice

Juvenile myelomonocytic leukemia is a childhood malignancy that lacks effective chemotherapies and thus has poor patient outcomes. PI3K p110δ has been found to promote hyperproliferation of cells expressing mutant Shp2. In this study, we tested the efficacy of a PI3Kδ inhibitor in mice expressing th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Lisa, Virts, Elizabeth L., Kapur, Reuben, Chan, Rebecca J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689572/ https://www.ncbi.nlm.nih.gov/pubmed/29156682 http://dx.doi.org/10.18632/oncotarget.21455

Ejemplares similares

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
por: Pongas, Georgios N., et al.
Publicado: (2017)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

ΔNp63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis
por: Di Franco, Simone, et al.
Publicado: (2016)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages
por: Goulielmaki, Evangelia, et al.
Publicado: (2018)

Role of aberrant PI3K pathway activation in gallbladder tumorigenesis
por: Lunardi, Andrea, et al.
Publicado: (2014)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells
por: Ramdas, Baskar, et al.
Publicado: (2022)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development
por: Alonso-Curbelo, Direna, et al.
Publicado: (2015)

The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
por: Patton, Daniel T., et al.
Publicado: (2011)

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds
por: Carrella, Diego, et al.
Publicado: (2016)

Structural basis of nSH2 regulation and lipid binding in PI3Kα
por: Miller, Michelle S., et al.
Publicado: (2014)

Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007)

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
por: Brana, Irene, et al.
Publicado: (2017)

PI3K/Akt promotes feedforward mTORC2 activation through IKKα
por: Dan, Han C., et al.
Publicado: (2016)

Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway
por: Yang, Fan, et al.
Publicado: (2019)

LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer
por: Henry, Whitney S., et al.
Publicado: (2016)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
por: Wei, Lei, et al.
Publicado: (2016)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors
por: Berndt, Alex, et al.
Publicado: (2010)

Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer
por: Ali, Khaled, et al.
Publicado: (2014)

Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury
por: Bilancio, Antonio, et al.
Publicado: (2017)

Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ
por: Hassenrück, Floyd, et al.
Publicado: (2023)

The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence
por: Thompson, Keyata N., et al.
Publicado: (2015)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer
por: Yang, Wei, et al.
Publicado: (2018)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
por: Lee, J. Scott, et al.
Publicado: (2015)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

Disrupted PI3K p110δ Signaling Dysregulates Maternal Immune Cells and Increases Fetal Mortality In Mice
por: Kieckbusch, Jens, et al.
Publicado: (2015)

Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β
por: Ito, Yoshihiro, et al.
Publicado: (2017)

Rapid development of myeloproliferative neoplasm in mice with Ptpn11(D61Y) mutation and haploinsufficient for Dnmt3a
por: Deng, Lisa, et al.
Publicado: (2017)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
por: Kurupi, Richard, et al.
Publicado: (2022)

The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation
por: Guo, Hailong, et al.
Publicado: (2008)

Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2016)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bcsdku7kdc0mo4g9fdnc4pdks2